Works matching AU Ailani, Jessica
Results: 78
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study.
- Published in:
- Journal of Headache & Pain, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s10194-021-01376-7
- By:
- Publication type:
- Article
Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
- Published in:
- Journal of Headache & Pain, 2020, v. 21, n. 1, p. 1, doi. 10.1186/s10194-020-01190-7
- By:
- Publication type:
- Article
An Unusual Case of Post-Traumatic Headache Complicated by Intracranial Hypotension.
- Published in:
- Brain Sciences (2076-3425), 2017, v. 7, n. 1, p. 3, doi. 10.3390/brainsci7010003
- By:
- Publication type:
- Article
Correction to: Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2–4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 3, p. 263, doi. 10.1007/s40261-021-01115-5
- By:
- Publication type:
- Article
Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
- Published in:
- JAMA Neurology, 2018, v. 75, n. 9, p. 1080, doi. 10.1001/jamaneurol.2018.1212
- By:
- Publication type:
- Article
Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis.
- Published in:
- Cephalalgia, 2024, v. 44, n. 12, p. 1, doi. 10.1177/03331024241299753
- By:
- Publication type:
- Article
Benefit-risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies.
- Published in:
- Cephalalgia, 2024, v. 44, n. 11, p. 1, doi. 10.1177/03331024241299377
- By:
- Publication type:
- Article
Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis.
- Published in:
- Cephalalgia, 2024, v. 44, n. 2, p. 1, doi. 10.1177/03331024241235156
- By:
- Publication type:
- Article
Open-label trials for CGRP-targeted drugs in migraine prevention: A narrative review.
- Published in:
- Cephalalgia, 2023, v. 43, n. 2, p. 1, doi. 10.1177/03331024221137091
- By:
- Publication type:
- Article
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
- Published in:
- Cephalalgia, 2022, v. 42, n. 1, p. 3, doi. 10.1177/03331024211042385
- By:
- Publication type:
- Article
Non-invasive vagus nerve stimulation for primary headache: A clinical update.
- Published in:
- Cephalalgia, 2020, v. 40, n. 12, p. 1370, doi. 10.1177/0333102420941864
- By:
- Publication type:
- Article
OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine over one year of treatment: Pooled results from the PREEMPT randomized clinical trial program.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
- Published in:
- European Journal of Neurology, 2024, v. 31, n. 2, p. 1, doi. 10.1111/ene.16131
- By:
- Publication type:
- Article
Reduction of pain and functional disability over time in patients treated with zavegepant: a post-hoc analysis of the BHV3500-301 phase 3 randomized controlled trial.
- Published in:
- Journal of Headache & Pain, 2025, v. 26, n. 1, p. 1, doi. 10.1186/s10194-024-01915-y
- By:
- Publication type:
- Article
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Clinical Efficacy and Safety of Ubrogepant for the Acute Treatment of Migraine.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Traditional and Novel Migraine Therapy in the Aging Population.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Diagnose and Adios: Practical Tips for the Ongoing Evaluation and Care of TAC Patients Taking Indomethacin.
- Published in:
- Current Pain & Headache Reports, 2015, v. 19, n. 2, p. 1, doi. 10.1007/s11916-014-0470-z
- By:
- Publication type:
- Article
Tension-Type Headache and Women: Do Sex Hormones Influence Tension-Type Headache?
- Published in:
- Current Pain & Headache Reports, 2010, v. 14, n. 6, p. 436, doi. 10.1007/s11916-010-0144-4
- By:
- Publication type:
- Article
Chronic tension-type headache.
- Published in:
- Current Pain & Headache Reports, 2009, v. 13, n. 6, p. 479, doi. 10.1007/s11916-009-0077-y
- By:
- Publication type:
- Article
The role of nerve blocks and botulinum toxin injections in the management of cluster headaches.
- Published in:
- Current Pain & Headache Reports, 2009, v. 13, n. 2, p. 164, doi. 10.1007/s11916-009-0028-7
- By:
- Publication type:
- Article
The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review.
- Published in:
- Pain & Therapy, 2023, v. 12, n. 3, p. 655, doi. 10.1007/s40122-023-00501-5
- By:
- Publication type:
- Article
What Is Combination Treatment in Migraine? Moving Toward a Uniform Definition of a Familiar Principle.
- Published in:
- Neurology & Therapy, 2024, v. 13, n. 6, p. 1535, doi. 10.1007/s40120-024-00669-8
- By:
- Publication type:
- Article
Evaluation of rimegepant utilization patterns and patient characteristics among new users: a United States administrative claims-based study.
- Published in:
- Current Medical Research & Opinion, 2024, v. 40, n. 11, p. 1913, doi. 10.1080/03007995.2024.2410930
- By:
- Publication type:
- Article
Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 10, p. 1253, doi. 10.1111/head.14824
- By:
- Publication type:
- Article
The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 8, p. 912, doi. 10.1111/head.14797
- By:
- Publication type:
- Article
Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 7, p. 859, doi. 10.1111/head.14775
- By:
- Publication type:
- Article
Calcitonin gene‐related peptide‐targeting therapies are a first‐line option for the prevention of migraine: An American Headache Society position statement update.
- Published in:
- Headache: The Journal of Head & Face Pain, 2024, v. 64, n. 4, p. 333, doi. 10.1111/head.14692
- By:
- Publication type:
- Article
Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 8, p. 1135, doi. 10.1111/head.14619
- By:
- Publication type:
- Article
Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 3, p. 418, doi. 10.1111/head.14485
- By:
- Publication type:
- Article
Phase Ib, open‐label, fixed‐sequence, drug–drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 3, p. 322, doi. 10.1111/head.14433
- By:
- Publication type:
- Article
Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing‐off of erenumab within monthly treatment cycle.
- Published in:
- Headache: The Journal of Head & Face Pain, 2023, v. 63, n. 2, p. 233, doi. 10.1111/head.14403
- By:
- Publication type:
- Article
Raynaud's phenomenon associated with calcitonin gene‐related peptide receptor antagonists case report.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 10, p. 1419, doi. 10.1111/head.14417
- By:
- Publication type:
- Article
Erenumab dosage for migraine prevention: An evidence‐based narrative review with recommendations.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 4, p. 420, doi. 10.1111/head.14266
- By:
- Publication type:
- Article
Patient preference for early onset of efficacy of preventive migraine treatments.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 3, p. 374, doi. 10.1111/head.14255
- By:
- Publication type:
- Article
Does "wearing off" of efficacy occur in galcanezumab‐treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 2, p. 198, doi. 10.1111/head.14257
- By:
- Publication type:
- Article
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
- Published in:
- 2022
- By:
- Publication type:
- Letter to the Editor
Combination CGRP monoclonal antibody and onabotulinumtoxinA treatment for preventive treatment in chronic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2022, v. 62, n. 1, p. 106, doi. 10.1111/head.14244
- By:
- Publication type:
- Article
Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 9, p. 1411, doi. 10.1111/head.14208
- By:
- Publication type:
- Article
Timing and durability of response to erenumab in patients with chronic migraine.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 8, p. 1255, doi. 10.1111/head.14193
- By:
- Publication type:
- Article
The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 7, p. 1021, doi. 10.1111/head.14153
- By:
- Publication type:
- Article
Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome.
- Published in:
- Headache: The Journal of Head & Face Pain, 2021, v. 61, n. 5, p. 766, doi. 10.1111/head.14120
- By:
- Publication type:
- Article
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 10, p. 2444, doi. 10.1111/head.13997
- By:
- Publication type:
- Article
Migraine Treatment in Pregnancy: An American Headache Society Survey.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 10, p. 2594, doi. 10.1111/head.13974
- By:
- Publication type:
- Article
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 5, p. 833, doi. 10.1111/head.13810
- By:
- Publication type:
- Article
Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 4, p. 686, doi. 10.1111/head.13766
- By:
- Publication type:
- Article
The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.
- Published in:
- Headache: The Journal of Head & Face Pain, 2020, v. 60, n. 2, p. 337, doi. 10.1111/head.13688
- By:
- Publication type:
- Article